RE: 6,12,24 month view2 Dec 2020 15:51
Broad spectrum antiviral won't be generating revenues this time next year. COPD won't be generating revenues this time next year. Our current P3 is for covid use, not broad spectrum and not copd. We'll need a lot more cash to progress the other two streams
Sp was highest at 2.60 at the peak of expectations that we will be selling SNG001 for covid imminently. £15-£20 a share without covid is absolutely delusional.
The company ex cash is currently valued at 29p and nobody wants to buy it by the looks of it. All this with start of P3 imminent and still a chance to cash in on the pandemic.
Do your own forecast from here.
If vaccines play out to be what they are claiming to be, curing covid as well as low IQ, aids, common cold and unwanted pregnancies, then we are a dead dog already.
If the vax fall through AND SNG pull the finger out their arses, we will fly.
About two weeks to find out if we are going to get any P3 action this year. If we are marked as a national priority, how the f.ck have we not been granted ethics yet?! For a drug with a long safety record and strong evidence to beat covid.